Drug Therapy for Chronic Pain

In many patients with chronic pain there is often a disparity between the degree of analgesic relief claimed by the patient and the ability to function better. The reasons for this are presented in a construct that suggests areas for consideration in any patient who is being considered for chronic analgesic use. Issues that influence perceived benefit are outlined. The importance of drug tolerance, dosage compliance, and patient's involvement in treatment are stressed. The use of contracts as an integral part of documented patient participation is outlined. Mechanisms that help in the handling of difficult patients are described. The use of physician extenders, anticipation of inappropriate patient behaviors, and prior expression of sanctions are shown to be helpful. The use of medications as part of the multidimensional care of the patient with chronic pain is discussed. This article presents practical solutions for difficulties encountered in managing patients with chronic pain.

Chronic pain - medication management - multidisciplinary care - compliance - contracts

REFERENCES

• 1 Eap C B, Bourquin M, Martin J et al.. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment.  Drug Alcohol Depend. 2000;  61 47-54
• 2 Woodhouse A, Ward M E, Mather L E. Intra-subject variability in post-operative patient-controlled analgesia (PCA): is the patient equally satisfied with morphine, pethidine and fentanyl?.  Pain. 1999;  80 545-553
• 3 Amanzio M, Pollow A, Maggi G et al.. Response variability to analgesics: a role for non-specific activation of endogenous opioids.  Pain. 2001;  90 205-215
• 4 Meagher M W, Arnau R C, Rhudy J L. Pain and emotion: effects of affective picture modulation.  Psychosom Med. 2001;  63 79-90
• 5 Meagher M W, Rhudy J L. Fear and anxiety: divergent effects on human pain thresholds.  Pain. 2000;  84 65-75
• 6 Marazziti D, Castrogiovanni P, Rossi A et al.. Pain threshold is reduced in depression.  Int J Neuropsychopharmacol. 1998;  1 45-48
• 7 Sarton E, Olofsen E, Romberg R et al.. Sex differences in morphine analgesia: an experimental study in healthy volunteers.  Anesthesiology. 2000;  93 1245-1254
• 8 Schwartz J B. Gender differences in response to drugs: pain medications.  J Gend Specif Med. 1999;  2 28-30
• 9 King B E, Alexander G M. Pain sensitivity and individual differences in self-reported sexual behavior.  J Comp Psychol. 2000;  114 193-199
• 10 Sun L S. Gender differences in pain sensitivity and responses to analgesia.  J Gend Specif Med. 1998;  1 28-30
• 11 Cimino R, Rarella M, Michelotti A et al.. Does the ovarian cycle influence the pressure-pain threshold of he masticatory muscles in symptom-free women?.  J Orofac Pain. 2000;  14 105-111
• 12 Zeichner A, Loftin M, Panopoulos G et al.. Sex differences in pain indices, exercise, and use of analgesics.  Psychol Rep. 2000;  86 129-133
• 13 Clauw D J, Williams D, Lauerman W et al.. Pain sensitivity as a correlate of clinical status in individuals with chronic low back pain.  Spine. 1999;  24 2035-2041
• 14 Bradley L A, McKendree-Smith N L, Alberts K R et al.. Use of neuroimaging to understand abnormal pain sensitivity in fibromyalgia.  Curr Rheumatol Rep. 2000;  2 141-148
• 15 Kosek E, Ordeberg G. Abnormalities of somatosensory perception in patients with painful osteoarthritis normalize following successful treatment.  Eur J Pain. 2000;  4 229-238
• 16 Bradley L A, McKendree-Smith N L, Alberts K R et al.. Use of neuroimaging to understand abnormal pain sensitivity in fibromyalgia.  Curr Rheumatol Rep. 2000;  2 141-148
• 17 Sheffield D, Biles P L, Orom H et al.. Race and sex differences in cutaneous pain perception.  Psychosom Med. 2000;  62 517-523
• 18 Compton P, Charuvastra V C, Kintaudi K et al.. Pain responses in methadone-maintained opioid abusers.  J Pain Symptom Manage. 2000;  20 237-245
• 19 Yamasaki H, Kakigi R, Watanabe S et al.. Effects of distraction on pain-related somatosensory evoked magnetic fields and potentials following painful electrical stimulation.  Brain Res Cogn Brain Res. 2000;  9 165-175
• 20 Keogh E, Hatton K, Ellery D. Avoidance versus focused attention and the perception of pain: differential effects for men and women.  Pain. 2000;  85 225-230
• 21 Kudoh A, Ishihara H, Matsuki A. Current perception thresholds and postoperative pain in schizophrenic patients.  Reg Anesth Pain Med. 2000;  25 475-479
• 22 Morin C, Lund J P, Villarroel T et al.. Differences between sexes in post-surgical pain.  Pain. 2000;  85 79-85
• 23 Seres J L. The fallacy of using 50% pain relief as the standard for satisfactory pain treatment outcome.  Pain Forum. 1999;  8 183-188
• 24 Price D D, Millin L S, Kirsch I et al.. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm.  Pain. 1999;  83 147-156
• 25 Wiesenfeld-Hallin Z, Alster P, Grass S et al.. Opioid sensitivity in antinociception: role of anti-opioid systems with emphasis on cholecystokinin and NMDA receptors. In: McQuay HJ, Wiesenfeld-Hallin Z Opioid Sensitivity of Chronic Non-Cancer Pain. Seattle; IASP Press 1999: 237-252
• 26 Amanzio M, Pollo A, Maggi G et al.. Response variability to analgesics: a role for non-specific activation of endogenous opioids.  Pain. 2001;  90 205-215
• 27 Jensen I B, Bodin L, Ljunqvist T et al.. Assessing the needs of patients in pain: a matter of opinion?.  Spine. 2000;  25 2816-2823
• 28 Loeser J D, Seres J L, Newman R I. Interdisciplinary, multimodal management of chronic pain. In: Bonica JJ, Loeser JD, Chapman CR, et al The Management of Pain. 2nd ed. Philadelphia; Lea & Febiger 1990: 2107-2120
• 29 Seres J L, Newman R I, Yospe L P et al.. Evaluation and management of chronic pain by nonsurgical means. In: Lee JF Pain Management: Symposium on the Neurosurgical Treatment of Pain. Baltimore; Williams & Wilkins 1977: 33-53
• 30 Jensen I B, Bodin L, Ljungqvist T et al.. Assessing the needs of patients in pain: a matter of opinion?.  Spine. 2000;  25 2816-2823
• 31 Mather L E, Cousins M J. The pharmacological relief of pain-contemporary issues.  Med J Aust. 1992;  156 796-802
• 32 Morley J S. New perspectives in our use of opioids.  Pain Forum. 1999;  8 200-205
• 33 Fallon M. Opioid rotation: does it have a role?.  Palliat Med. 1997;  11 177-178
• 34 Galer B S, Coyle N, Pasternak G W et al.. Individual variability in the response to different opioids: report of five cases.  Pain. 1992;  49 87-91
• 35 Makin M K, Ellershaw J E. Substitution of another opioid for morphine. Methadone can be used to manage neuropathic pain related to cancer.  BMJ. 1998;  317(7150) 81
• 36 Eide P K, Jorum E, Stubhaug A et al.. Relief of post-herpetic neuralgia with the N-methyl-D-aspartate (NMDA) antagonist ketamine: a double blind, cross-over comparison with morphine and placebo.  Pain. 1994;  58 347-354
• 37 Elliott K, Kest B, Man A et al.. N-Methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development.  Neuropsychopharmacology. 1995;  13 347-356
• 38 Celerier E, Laulin J, Larcher A et al.. Evidence for opiate-activated NMDA processes masking opiate analgesia in rats.  Brain Res. 1999;  847 18-25
• 39 Mobarakeh J I, Sakurada S, Katsuyama S et al.. Role of histamine H(1) receptor in pain perception: a study of the receptor gene knockout mice.  Eur J Pharmacol. 2000;  391 81-90
• 40 Bohn L M, Gaionetdinov R R, Lin F T et al.. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence.  Nature. 2000;  408 720-723
• 41 Williams J T, Christie M J, Manzoni O. Cellular and synaptic adaptations mediating opioid dependence.  Physiol Rev. 2001;  81 299-343
• 42 Weinstein S M, Laux L F, Thornby J I et al.. Physicians’ attitudes toward pain and the use of opioid analgesics: results of a survey fro the Texas Cancer Pain Initiative.  South Med J. 2000;  93 479-487
• 43 Hung C, Liu C, Chen C et al.. Meperidine addiction or treatment frustration?.  Gen Hosp Psychiatry. 2001;  23 31-35
• 44 Vanderah T W, Ossipov M H, Lai J et al.. Mechanisms of opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal dynorphin.  Pain. 2001;  92 5-9
• 45 Am S, Rawal N, Gustafsson L L. Clinical experience of long-term treatment with epidural and intrathecal opioids-a nationwide survey.  Acta Anaesthesiol Scand. 1988;  32 253-259
• 46 Gutstein H B. The effects of pain on opioid tolerance: how do we resolve the controversy?.  Pharmacol Rev. 1996;  48 403-407
• 47 Vanderah T W, Suenaga N MH, Ossipov M H et al.. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance.  J Neurosci. 2001;  21 279-283
• 48 Curatolo M, Bogduk N. Pharmacologic pain treatment of musculoskeletal disorders: current perspectives and future prospects.  Clin J Pain. 2001;  17 25-32
• 49 Spitzer W O, Skovron M L, Salmi L R. Scientific monograph of the Quebec Task Force on Whiplash-Associated Disorders: redefining ‘whiplash’ and its management.  Spine. 1995;  20(suppl) 1S-73S
• 50 Koes B W, Scholten R J, Mens J M et al.. Efficacy of non-steroidal anti-inflammatory drugs for low back pain: a systematic review of randomized clinical trials.  Ann Rheum Dis. 1997;  56 214-223
• 51 Grond S, Radbruch L, Lehmann K A. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl.  Clin Pharmacokinet. 2000;  38 59-89
• 52 Jensen T S. Mechanisms of neuropathic pain. In: Campbell JV Pain: An Updated Review. Seattle; IASP Press 1996: 76-86
• 53 Sindrup S H, Jensen T S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action.  Pain. 1999;  83 389-400
• 54 Sindroup S H. Antidepressants as analgesics. In: Yaksh TL, Lynch C, Zapol VM, et al Anesthesia. Biologic Foundations. Philadelphia; Lippincott-Raven 1997: 987-997
• 55 Hrobjartsson A, Gotzsche P C. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment.  N Engl J Med. 2001;  344 1594-1602
• 56 Bailar J C. The powerful placebo and the Wizard of Oz.  N Engl J Med. 2001;  344 1630-1632
• 57 Liliana De Lima M H, Sakowski J A, Stratton Hill C et al.. Legislation analysis according to WHO and INCB criteria on opioid availability; a comparative study of five countries and the state of Texas.  Health Policy. 2001;  56 99-110
• 58 Beaver W T. In: Aronoff GM Evaluation and Treatment of Chronic Pain. 3rd ed. Baltimore; Williams & Wilkins 1999: 455
• 59 Daoud K F, Jackson C G, Williams H J. Basic therapy for rheumatoid arthritis: nonsteroidal anti-inflammatory drugs.  Compr Ther. 1999;  25 427-433
• 60 Med Lett. 2000;  42 74
• 61 Dionne R A, Lepinski A M, Gordon S M et al.. Analgesic effects of peripherally administered opioids in clinical models of acute and chronic inflammation.  Clin Pharmacol Ther. 2001;  70 66-73
• 62 Szeto H H, Lovelace J L, Fridland G et al.. In vivo pharmacokinetics of selective mu-opioid peptide agonists.  J Pharmacol Exp Ther. 2001;  298 57-61
• 63 Lucas A C, Bermejo A M, Tabernero M J et al.. Influence of concomitant drugs on methadone elimination half-life in patients under a maintenance treatment.  Addict Biol. 2001;  6 171-176
• 64 Gardner J S, Blough D, Drinkard C R et al.. Tramadol and seizures: a surveillance study in a managed care population.  Pharmacotherapy. 2000;  20 1423-1431
• 65 Robards M. Transdermal fentanyl in the hospice: a survey of rescue dosing and pain control.  Am J Hosp Palliat Care. 2001;  18 47-50
• 66 West S L, O'Neal K K, Graham C W. A meta-analysis comparing the effectiveness of buprenorphine and methadone.  J Subst Abuse. 2000;  12 405-414
• 67 Preston K L, Bigelow G E. Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination.  J Pharmacol Exp Ther. 2000;  295 114-124
• 68 Kingery W S. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes.  Pain. 1997;  73 123-139
• 69 Orza F, Boswell M V, Rosenberg S K. Neuropathic pain: review of mechanisms and pharmacologic management.  Neurorehabilitation. 2000;  14 15-23
• 70 Barkin R L, Fawcett J. The management challenges of chronic pain: the role of antidepressants.  Am J Ther. 2000;  7 31-47
• 71 Hemstreet B, Lapointe M. Evidence for the use of gabapentin in the treatment of diabetic peripheral neuropathy.  Clin Ther. 2001;  23 520-531
• 72 Seres J L. Approach to the patient with pain. In: Follett KA Neurosurgical Pain Management. Philadelphia; Elsevier Sanders 2004: 3-16
• 73 Coughlin A M, Badura A S, Fleischer T D et al.. Multidisciplinary treatment of chronic pain patients: its efficacy in changing patient locus of control.  Arch Phys Med Rehabil. 2000;  81 739-740
• 74 Fishman S M, Wilsey B, Yang J et al.. Adherence monitoring and drug surveillance in chronic opioid therapy.  J Pain Symptom Manage. 2000;  20 293-307
• 75 Mahoney N D, Devine J E, Angres D. Multidisciplinary treatment of benign chronic pain syndrome in substance abusing patients.  Curr Rev Pain. 1999;  3 321-331
• 76 Sjogren P, Thomsen A B, Olsen A K. Impaired neuropsychological performance in chronic nonmalignant pain patients receiving long-term oral opioid therapy.  J Pain Symptom Manage. 2000;  19 100-108
• 77 Gregory R J, Manring J, Berry S L. Pain location and psychological characteristics of patients with chronic pain.  Psychosomatics. 2000;  41 216-220
• 78 Winfield J B. Psychological determinants of fibromyalgia and related syndromes.  Curr Rev Pain. 2000;  4 276-286
• 79 Blier P, Abbott F V. Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain.  J Psychiatry Neurosci. 2001;  26 37-43
• 80 Brennscheidt U, Seiler K U, Thomman P. Pharmacokinetics of nortilidine and naloxone after administration of tilidine/naloxone solution or tilidine/naloxone sustained release.  Arzneimittelforschung. 2000;  50 1015-1022
• 81 Fuentes J A, Ruiz-Gayo M, Manzanares J et al.. Cannabinoids as potential new analgesics.  Life Sci. 1999;  65 675-685
• 82 Shipton E A. Tramadol-present and future.  Anaesth Intensive Care. 2000;  28 363-374
• 83 McCleane G J. The cholecystokinin antagonist proglumide enhances the analgesic efficacy of morphine in humans with chronic benign pain.  Anesth Analg. 1998;  87 1117-1120
• 84 Arends R H, Hayashi T G, Luger T J et al.. Cotreatment with racemic fenfluramine inhibits the development of tolerance to morphine analgesia in rats.  J Pharmacol Exp Ther. 1998;  286 585-592
• 85 Ozturk Y. Kinin receptors and their antagonists as novel therapeutic agents.  Curr Pharm Des. 2001;  7 135-161
• 86 Hewitt D J. The use of NMDA-receptor antagonists in the treatment of chronic pain.  Clin J Pain. 2000;  16 S73-S79
• 87 Chevlen E. Morphine with dextromethorphan: conversion from other opioid analgesics.  J Pain Symptom Manage. 2000;  19 S42-S49
• 88 Rapaka R S, Porreca F. Development of delta opioid peptides as nonaddicting analgesics.  Pharm Res. 1991;  8 1-8
• 89 Koepp M J, Duncan J S. PET: opiate neuroreceptor mapping.  Adv Neurol. 2000;  83 145-156